AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9713731 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% oxygen for 15 minutes on each of the 3 postoperative days
Number of subjects: 24
Study 8045060 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium citrate (Citramag)
Number of subjects: 100
Study 8045060 — intervention group
Group type: COMPARATOR
Intervention: Picolax
Number of subjects: 100
Study 3409620 — intervention group
Group type: COMPARATOR
Intervention: Single oral dose of 200 mg of [15N]glycine as a tracer
Number of subjects: 0
Study 31588561 — intervention group
Group type: EXPERIMENTAL
Intervention: PGY5 trainees
Number of subjects: 19
Study 31588561 — intervention group
Group type: COMPARATOR
Intervention: PGY3 trainees
Number of subjects: 19
Study 31588561 — intervention group
Group type: EXPERIMENTAL
Intervention: Examination overall
Number of subjects: 19
Study 28961980 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic adjunct therapy
Number of subjects: 33
Study 28961980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 27144828 — intervention group
Group type: EXPERIMENTAL
Intervention: Stem cells cultured on beta‐TCP in combination with rh‐PDGF‐BB
Number of subjects: 14
Study 23460053 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 4675
Study 23460053 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated
Number of subjects: 4675
Study 23460053 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted
Number of subjects: 4675
Study 23460053 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigated
Number of subjects: 4675
Study 21358354 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidental durotomy group
Number of subjects: 409
Study 21358354 — intervention group
Group type: COMPARATOR
Intervention: No incidental durotomy group
Number of subjects: 409
Study 21358354 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 409
Study 18305079 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK (Glucose‐insulin‐potassium) group
Number of subjects: 44
Study 18305079 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study 16572016 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening removal of urinary catheters at 22:00 hours
Number of subjects: 210
Study 16572016 — intervention group
Group type: COMPARATOR
Intervention: Morning removal of urinary catheters at 06:00 hours
Number of subjects: 210
Study 14665656 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (levothyroxine reduced by 50 micro g/d and substituted with liothyronine, 7.5 micro g, taken twice daily for 4 months)
Number of subjects: 46
Study 14665656 — intervention group
Group type: COMPARATOR
Intervention: Levothyroxine alone (usual dose)
Number of subjects: 46
Study 14665656 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (levothyroxine plus liothyronine)
Number of subjects: 46
Study 11319567 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 18
Study 11319567 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release verapamil
Number of subjects: 18
Study 11319567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 8857434 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine infusion (6 mu g kg‐1 min‐1)
Number of subjects: 16
Study 8857434 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dobutamine)
Number of subjects: 16
Study 1627200 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% sertaconazole dermatological cream
Number of subjects: 78
Study 1627200 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 other commercially available antimycotics (econazole, ketoconazole, bifonazole, clotrimazole, miconazole)
Number of subjects: 78
Study 1627200 — intervention group
Group type: COMPARATOR
Intervention: Excipient of the cream without sertaconazole
Number of subjects: 78
Study 1627200 — intervention group
Group type: COMPARATOR
Intervention: 2% sertaconazole in vaseline
Number of subjects: 78
Study 6373426 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximized metabolic control (multiple insulin injections daily or insulin pumps)
Number of subjects: 32
Study 6373426 — intervention group
Group type: COMPARATOR
Intervention: Standard control (one or more injections of insulin daily)
Number of subjects: 32
Study 30169797 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally targeted Courage to Quit (CTQ-CT) smoking cessation treatment
Number of subjects: 345
Study 30169797 — intervention group
Group type: COMPARATOR
Intervention: Standard Courage to Quit (CTQ) smoking cessation intervention
Number of subjects: 345
Study 27390305 — intervention group
Group type: EXPERIMENTAL
Intervention: LigaSure Small Jaw®
Number of subjects: 41
Study 27390305 — intervention group
Group type: COMPARATOR
Intervention: Conventional neck dissection
Number of subjects: 41
Study 26301923 — intervention group
Group type: EXPERIMENTAL
Intervention: Written information
Number of subjects: 1676
Study 26301923 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone information
Number of subjects: 1676
Study 26301923 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face information
Number of subjects: 1676
Study 26301923 — intervention group
Group type: COMPARATOR
Intervention: Control group (no briefing)
Number of subjects: 1676
Study 24225668 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 20
Study 24225668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 21652220 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxercalciferol capsules (conversion factors: 0.5, 1.0, 1.5 times the current paricalcitol dose)
Number of subjects: 0
Study 21652220 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxercalciferol capsules (conversion factors: 1.0, 1.5, 2.0 times the current doxercalciferol injection dose)
Number of subjects: 0
Study 21652220 — intervention group
Group type: COMPARATOR
Intervention: Doxercalciferol capsules
Number of subjects: 0
Study 21039051 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography screening
Number of subjects: 86
Study 21039051 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge about mammography
Number of subjects: 86
Study 21039051 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of mammogram frequency
Number of subjects: 86
Study 21039051 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of mammogram side effects
Number of subjects: 86
Study 21039051 — intervention group
Group type: EXPERIMENTAL
Intervention: Early detection knowledge
Number of subjects: 86
Study 17554581 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral risedronate 2.5 mg/day for 6 months
Number of subjects: 43
Study 17554581 — intervention group
Group type: COMPARATOR
Intervention: No osteoactive drug (Control)
Number of subjects: 43
Study 15893211 — intervention group
Group type: EXPERIMENTAL
Intervention: Making a risk estimate prior to receiving risk information
Number of subjects: 356
Study 15893211 — intervention group
Group type: COMPARATOR
Intervention: Not making a risk estimate prior to receiving risk information
Number of subjects: 356
Study 12584837 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuzheng Qubi Decoction (FZQBD)
Number of subjects: 30
Study 12584837 — intervention group
Group type: COMPARATOR
Intervention: Western medicine combination therapy
Number of subjects: 30
Study 9849278 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithotomy positioning (n = 12)
Number of subjects: 36
Study 9849278 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia (n = 12)
Number of subjects: 36
Study 9849278 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia in the supine position (n = 12)
Number of subjects: 36
Study 8181590 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative intra-arterial chemotherapy
Number of subjects: 0
Study 8181590 — intervention group
Group type: EXPERIMENTAL
Intervention: More effective drugs and less demanding regimens
Number of subjects: 0
Study 2678857 — intervention group
Group type: EXPERIMENTAL
Intervention: Transversalis fascia-Cooper ligament (McVay) repair
Number of subjects: 171
Study 2678857 — intervention group
Group type: COMPARATOR
Intervention: Transversalis fascia-ileopubic tract (Ottsen) repair
Number of subjects: 171
Study 138560 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline 50 mg twice daily
Number of subjects: 0
Study 138560 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline 250 mg twice daily
Number of subjects: 0
Study 31722700 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial prophylaxis (AMP) discontinued within 24 hours after surgery
Number of subjects: 1000
Study 31722700 — intervention group
Group type: COMPARATOR
Intervention: Antimicrobial prophylaxis (AMP) discontinued within 24-48 hours after surgery
Number of subjects: 1000
Study 31722700 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (24h and 48h)
Number of subjects: 1000
Study 28566393 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite coated acetabular component (group 1)
Number of subjects: 302
Study 28566393 — intervention group
Group type: EXPERIMENTAL
Intervention: Macrotexture acetabular component (group 2)
Number of subjects: 302
Study 25912621 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula scoring (FS)
Number of subjects: 337
Study 25912621 — intervention group
Group type: EXPERIMENTAL
Intervention: Don't know option (DKO)
Number of subjects: 337
Study 25912621 — intervention group
Group type: COMPARATOR
Intervention: Number-right (NR) scores
Number of subjects: 337
Study 24289591 — intervention group
Group type: EXPERIMENTAL
Intervention: Recall letter for a repeat smear
Number of subjects: 1000
Study 24289591 — intervention group
Group type: EXPERIMENTAL
Intervention: Registered letter
Number of subjects: 1000
Study 24289591 — intervention group
Group type: EXPERIMENTAL
Intervention: Short messages services (SMS)
Number of subjects: 1000
Study 24289591 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone calls
Number of subjects: 1000
Study 21738077 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 g/day TU-025
Number of subjects: 178
Study 21738077 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 g/day TU-025
Number of subjects: 178
Study 21738077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study 19321019 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive approaches to understanding and treating positive psychotic symptoms.
Number of subjects: 0
Study 19321019 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive appraisal dimensions and reasoning styles (inferential confusion, cognitive slippage, fantasy proneness, perceptual immersion).
Number of subjects: 0
Study 16500490 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast echocardiography (CE)
Number of subjects: 36
Study 16500490 — intervention group
Group type: COMPARATOR
Intervention: Gated single photon emission computed tomography (SPECT)
Number of subjects: 36
Study 14634170 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride toothpaste and mouthrinse
Number of subjects: 6
Study 14634170 — intervention group
Group type: COMPARATOR
Intervention: No fluoride toothpaste and mouthrinse
Number of subjects: 6
Study 14634170 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo fluoride release
Number of subjects: 6
Study 14634170 — intervention group
Group type: COMPARATOR
Intervention: In vitro fluoride release
Number of subjects: 6
Study 10690824 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulbar conjunctival blood column (BCBC)
Number of subjects: 0
Study 10690824 — intervention group
Group type: EXPERIMENTAL
Intervention: Palpebral conjunctival hue (PCH)
Number of subjects: 0
Study 9322458 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (4 mg)
Number of subjects: 158
Study 9322458 — intervention group
Group type: COMPARATOR
Intervention: Droperidol (20 micrograms/kg)
Number of subjects: 158
Study 9322458 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 158
Study 9322458 — intervention group
Group type: COMPARATOR
Intervention: Droperidol
Number of subjects: 158
Study 8095127 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg twice daily)
Number of subjects: 25
Study 8095127 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine (20 mg twice daily)
Number of subjects: 25
Study 8095127 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine (150 mg twice daily)
Number of subjects: 25
Study 8095127 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg twice daily)
Number of subjects: 25
Study 8095127 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 25
Study 3555898 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer Factor (TF)
Number of subjects: 45
Study 31538372 — intervention group
Group type: EXPERIMENTAL
Intervention: Osmotic-Release Oral System Methylphenidate (OROS‐MPH)
Number of subjects: 134
Study 29414612 — intervention group
Group type: EXPERIMENTAL
Intervention: Adductor Canal Block (ACB)
Number of subjects: 40
Study 29414612 — intervention group
Group type: COMPARATOR
Intervention: Local Infiltration Analgesia (LIA)
Number of subjects: 40
Study 26470053 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 272
Study 26470053 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 272
Study 24226490 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintaining cuff pressure at 60 cmH2O in PSV group
Number of subjects: 120
Study 24226490 — intervention group
Group type: COMPARATOR
Intervention: No intervention in cuff pressure in PSV group
Number of subjects: 120
Study 24226490 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintaining cuff pressure at 60 cmH2O (all ventilation modes)
Number of subjects: 120
Study 24226490 — intervention group
Group type: COMPARATOR
Intervention: No intervention in cuff pressure (all ventilation modes)
Number of subjects: 120
Study 22171794 — intervention group
Group type: EXPERIMENTAL
Intervention: REDUSTIM(®) device (alternate low frequency electromagnetic fields and controlled micropressure) for 12 sessions over 6 weeks
Number of subjects: 28
Study 22171794 — intervention group
Group type: EXPERIMENTAL
Intervention: REDUSTIM(®) device
Number of subjects: 28
Study 19006068 — intervention group
Group type: EXPERIMENTAL
Intervention: Real ultrasound (US) treatment
Number of subjects: 12
Study 19006068 — intervention group
Group type: COMPARATOR
Intervention: Sham ultrasound (US) treatment
Number of subjects: 12
Study 17199580 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg once weekly
Number of subjects: 265
Study 17199580 — intervention group
Group type: COMPARATOR
Intervention: Etanercept 25 mg twice weekly
Number of subjects: 265
Study 16261462 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 50 mg followed immediately by propofol LCT 2 mg.kg(‐1)
Number of subjects: 250
Study 16261462 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 50 mg followed by propofol LCT 2 mg.kg(‐1) 1 min later
Number of subjects: 250
Study 16261462 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% Lidocaine 40 mg followed immediately by propofol LCT 2 mg.kg(‐1)
Number of subjects: 250
Study 16261462 — intervention group
Group type: COMPARATOR
Intervention: Propofol LCT 2 mg.kg(‐1) alone
Number of subjects: 250
Study 16261462 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol in a mixture of medium‐chain triglyceride (MCT) and LCT 2 mg.kg(‐1)
Number of subjects: 250
Study 11895791 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-Helicobacter pylori treatment
Number of subjects: 189
Study 11895791 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular follow-up analysis
Number of subjects: 189
Study 11895791 — intervention group
Group type: COMPARATOR
Intervention: Presence of molecular disease
Number of subjects: 189
Study 9861141 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine premedication
Number of subjects: 30
Study 9861141 — intervention group
Group type: COMPARATOR
Intervention: No atropine premedication (Control)
Number of subjects: 30
Study 7725129 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in a demonstration project to improve patient care
Number of subjects: 418
Study 7725129 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic characteristics of community pharmacists
Number of subjects: 418
Study 2547560 — intervention group
Group type: EXPERIMENTAL
Intervention: nedocromil sodium 4mg
Number of subjects: 12
Study 2547560 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 10798 — intervention group
Group type: EXPERIMENTAL
Intervention: Solcoseryl and Proglumide (systematic preventive treatment)
Number of subjects: 68
Study 10798 — intervention group
Group type: COMPARATOR
Intervention: No specific treatment (Control group)
Number of subjects: 68
Study 30808512 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐Nav Insulin Guidance System with health‐care professional support
Number of subjects: 181
Study 30808512 — intervention group
Group type: COMPARATOR
Intervention: Health‐care professional support alone
Number of subjects: 181
Study 28072863 — intervention group
Group type: EXPERIMENTAL
Intervention: 30mg/kg of oral azithromycin
Number of subjects: 247
Study 28072863 — intervention group
Group type: COMPARATOR
Intervention: 50,000 units/kg of intramuscular benzathine penicillin
Number of subjects: 247
Study 26264718 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (HC) >20 mg/day
Number of subjects: 53
Study 26264718 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (HC) (all doses)
Number of subjects: 53
Study 26264718 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone (HC) ≤20 mg/day
Number of subjects: 53
Study 23794107 — intervention group
Group type: EXPERIMENTAL
Intervention: tolcapone (100 mg three times a day for 1 day and then 200 mg three times a day for 6 days)
Number of subjects: 20
Study 23794107 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 21183746 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 0
Study 21183746 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone
Number of subjects: 0
Study 19758969 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (0.75 mg/kg)
Number of subjects: 17
Study 19758969 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadroparin (70.4 IU/kg)
Number of subjects: 17
Study 19758969 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin (78.6 IU/kg)
Number of subjects: 17
Study 19758969 — intervention group
Group type: COMPARATOR
Intervention: Control (no heparin)
Number of subjects: 17
Study 16679905 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaseline gauze (VD)
Number of subjects: 33
Study 16679905 — intervention group
Group type: EXPERIMENTAL
Intervention: Biobrane (BD)
Number of subjects: 33
Study 16679905 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusive film dressing Barrier Flex (OD)
Number of subjects: 33
Study 16679905 — intervention group
Group type: EXPERIMENTAL
Intervention: Equine collagen foil, Tissu Foil E (CD)
Number of subjects: 33
Study 16679905 — intervention group
Group type: COMPARATOR
Intervention: Control (uninjured skin)
Number of subjects: 33
Study 15762391 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed model approach for assessment of interventions
Number of subjects: 0
Study 11318058 — intervention group
Group type: EXPERIMENTAL
Intervention: Variation of the arm's mass distribution combined with prism adaptation
Number of subjects: 0
Study 11318058 — intervention group
Group type: EXPERIMENTAL
Intervention: Prism adaptation
Number of subjects: 0
Study 11318058 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulations of plane of motion, body posture, proprioceptive target, and proprioceptive experience during prism adaptation
Number of subjects: 0
Study 9863076 — intervention group
Group type: EXPERIMENTAL
Intervention: Shuxuening (SXN) 120 mg three times daily
Number of subjects: 545
Study 9863076 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 545
Study 9863076 — intervention group
Group type: EXPERIMENTAL
Intervention: Shuxuening (SXN)
Number of subjects: 545
Study 8181219 — intervention group
Group type: EXPERIMENTAL
Intervention: tiapride (200 mg/die)
Number of subjects: 20
Study 8181219 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 3540084 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (activity group, n = 113)
Number of subjects: 224
Study 3540084 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 111)
Number of subjects: 224
Study 31876643 — intervention group
Group type: EXPERIMENTAL
Intervention: POC+PM
Number of subjects: 226
Study 31876643 — intervention group
Group type: COMPARATOR
Intervention: POC
Number of subjects: 226
Study 31876643 — intervention group
Group type: EXPERIMENTAL
Intervention: Change Process Capability Questionnaire
Number of subjects: 226
Study 30544449 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgiflo Haemostatic Matrix (SHM)
Number of subjects: 60
Study 30544449 — intervention group
Group type: COMPARATOR
Intervention: Absorbable Gelatin Sponge (AGS)
Number of subjects: 60
Study 26956651 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based parenting intervention
Number of subjects: 60
Study 26956651 — intervention group
Group type: COMPARATOR
Intervention: Standard pediatric primary care
Number of subjects: 60
Study 25275422 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor-induced pain during PASAT performance
Number of subjects: 72
Study 25275422 — intervention group
Group type: COMPARATOR
Intervention: Painless room-temperature water immersion during PASAT performance
Number of subjects: 72
Study 23838501 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diltiazem gel (2ml of 2% topical diltiazem gel)
Number of subjects: 73
Study 23838501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 20965465 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1056
Study 20965465 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 1056
Study 20965465 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 1056
Study 20965465 — intervention group
Group type: COMPARATOR
Intervention: PCI
Number of subjects: 1056
Study 17899340 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye-closure during retrieval
Number of subjects: 5